NCT00329043 - Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2006

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Prostate Cancer

Interventions

DRUG

LHRH Agonist

Intramuscular injection either monthly for 3 months or in a single 3-month dose.

DRUG

Sunitinib Malate

25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.

PROCEDURE

Radical Prostatectomy

Radical prostatectomy after completion of Sunitinib and LHRH agonist.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston